Clinical Trial Update: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Neugranin in breast cancer patients receiving doxorubicin/docetaxel for chemotherapy-induced neutropenia has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Neutropenia

Drugs mentioned

• Neugranin (Neugranin)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chemotherapy-induced Neutropenia | Phase 3 | Status: COMPLETED | Results posted: 2023-03-28